Holen Sie sich die Stockscreener-App
33.23
4.33%
-1.505
Schlusskurs vom Vortag:
$34.73
Offen:
$34.38
24-Stunden-Volumen:
643.57K
Relative Volume:
1.30
Marktkapitalisierung:
$1.06B
Einnahmen:
$780.57M
Nettoeinkommen (Verlust:
$62.87M
KGV:
19.35
EPS:
1.7171
Netto-Cashflow:
$327.58M
1W Leistung:
-6.97%
1M Leistung:
-26.43%
6M Leistung:
-5.49%
1J Leistung:
+8.74%
1-Tages-Spanne:
$32.86
$34.84
1-Wochen-Bereich:
$32.86
$36.88
52-Wochen-Spanne:
$23.23
$50.79
Collegium Pharmaceutical Inc Stock (COLL) Company Profile
Firmenname
Collegium Pharmaceutical Inc
Sektor
Telefon
781-713-3699
Adresse
100 TECHNOLOGY CENTER DRIVE, STOUGHTON, MA
Compare COLL vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
COLL
Collegium Pharmaceutical Inc
|
33.23 | 1.06B | 780.57M | 62.87M | 327.58M | 1.7171 |
TAK
Takeda Pharmaceutical Co Adr
|
18.04 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.93 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.14 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
531.82 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Collegium Pharmaceutical Inc Stock (COLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-01-10 | Hochstufung | Needham | Hold → Buy |
| 2024-07-30 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-06-07 | Hochstufung | Jefferies | Hold → Buy |
| 2024-05-10 | Herabstufung | Needham | Buy → Hold |
| 2024-05-10 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-01-04 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-25 | Bestätigt | Needham | Buy |
| 2023-05-02 | Fortgesetzt | Jefferies | Buy |
| 2022-08-08 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-02-15 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-08-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-14 | Eingeleitet | BWS Financial | Sell |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-19 | Fortgesetzt | Jefferies | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-03 | Fortgesetzt | H.C. Wainwright | Buy |
| 2019-04-12 | Fortgesetzt | Janney | Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2019-01-16 | Bestätigt | Needham | Buy |
| 2018-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2018-02-07 | Bestätigt | Needham | Buy |
| 2017-12-05 | Bestätigt | Needham | Buy |
| 2017-09-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-05-11 | Bestätigt | Needham | Buy |
| 2016-09-13 | Eingeleitet | Gabelli & Co | Buy |
| 2015-06-01 | Eingeleitet | Jefferies | Buy |
| 2015-06-01 | Eingeleitet | Needham | Buy |
| 2015-06-01 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Collegium Pharmaceutical Inc Aktie (COLL) Neueste Nachrichten
Collegium Pharmaceutical, Inc. (COLL) Discusses Acquisition of AZSTARYS to Expand ADHD Portfolio and Accelerate GrowthSlideshow (NASDAQ:COLL) 2026-03-24 - Seeking Alpha
Collegium Pharmaceutical Stock Gains Momentum After Key Debt Repayment and Strong Earnings Momentum - AD HOC NEWS
Collegium Pharmaceutical (COLL) Valuation Check After Recent Share Price Volatility - Sahm
Insider Selling: Collegium Pharmaceutical (NASDAQ:COLL) EVP Sells 13,976 Shares of Stock - MarketBeat
Dieter David, Collegium Pharmaceutical EVP, sells $488k in stock By Investing.com - Investing.com Canada
Collegium (NASDAQ: COLL) EVP trades 13,976 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceuticals: Another M&A Episode Adds To An Intriguing Case (NASDAQ:COLL) - Seeking Alpha
Collegium Pharmaceutical stock faces scrutiny amid opioid market shifts and regulatory pressures - AD HOC NEWS
Pharma M&A Roundup: Novartis to Acquire Pan-Mutant-Selective PI3Kα Inhibitor from Synnovation Therapeutics, Collegium to Acquire Azstarys from Corium Therapeutics - Pharmaceutical Executive
Azstarys (re-)born with Collegium’s ADHD buy - BioWorld MedTech
Collegium Pharmaceutical Expands ADHD Portfolio With AZSTARYS And Valuation Gap - simplywall.st
Needham & Company LLC Reiterates Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL) - MarketBeat
Collegium Pharmaceutical (NASDAQ:COLL) Given Buy Rating at HC Wainwright - MarketBeat
Collegium to acquire Azstarys from Corium Therapeutics - The Pharma Letter
Collegium Pharmaceutical to Acquire AZSTARYS® for $650 Million, Expanding ADHD Portfolio and Projecting Over $50 Million Revenue in Late 2026 - Minichart
Collegium Pharmaceutical to acquire AZSTARYS for $650 million By Investing.com - Investing.com Australia
Jefferies reiterates Collegium Pharmaceutical stock Buy on ADHD deal By Investing.com - Investing.com Canada
Collegium Pharmaceutical to Acquire AZSTARYS ADHD Franchise - TipRanks
Collegium (NASDAQ: COLL) to acquire AZSTARYS in $650M ADHD expansion deal - Stock Titan
Barclays reiterates Collegium Pharmaceutical stock rating at Overweight By Investing.com - Investing.com Canada
Collegium Pharmaceutical (NASDAQ:COLL) Shares Gap UpShould You Buy? - MarketBeat
Collegium ponies up $650M to gain ADHD drug Azstarys from Corium - Fierce Pharma
Collegium Pharmaceutical to acquire Corium's ADHD drug for up to $785 million - marketscreener.com
Collegium Pharmaceutical to Buy AZSTARYS for $650M, Expanding ADHD Franchise Through 2037 - MarketBeat
Collegium Pharmaceutical to acquire AZSTARYS for $650 million - Investing.com
Collegium Pharmaceutical to Acquire Azstarys From Corium Therapeutics for $650 Million in Cash - marketscreener.com
Collegium to Acquire AZSTARYS® from Corium Therapeutics, - GlobeNewswire
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory - Sahm
Fidelity lists 13,976 COLL shares for sale (NASDAQ: COLL) - Stock Titan
Whale Trades: What are analysts price targets for Collegium Pharmaceutical Inc2026 EndofMonth & Expert Curated Trade Setup Alerts - baoquankhu1.vn
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know - Yahoo Finance
Member Spotlight: Collegium Pharmaceutical - Massachusetts Biotechnology Council
Collegium Pharmaceutical, Inc. $COLL Position Reduced by Eventide Asset Management LLC - MarketBeat
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference - MarketBeat
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pressure - Yahoo Finance
3 Healthcare Stocks Walking a Fine Line - The Globe and Mail
Insider Sell: David Dieter Sells Shares of Collegium Pharmaceuti - GuruFocus
Risk Recap: What is the dividend yield of Collegium Pharmaceutical IncIndex Update & Weekly Setup with ROI Potential - baoquankhu1.vn
Collegium (NASDAQ: COLL) EVP sells 6,224 shares under 10b5-1 plan - Stock Titan
Collegium Pharmaceutical at Barclays Conference: Strategic Growth and Challenges By Investing.com - Investing.com Canada
WINTON GROUP Ltd Purchases Shares of 65,345 Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Victory Capital Management Inc. Cuts Stock Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results - Insider Monkey
Jefferies Financial Group Inc. Takes $4.43 Million Position in Collegium Pharmaceutical, Inc. $COLL - MarketBeat
Assessing Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Weakness - simplywall.st
[144] COLLEGIUM PHARMACEUTICAL, INC SEC Filing - Stock Titan
Market Catalysts: Can Collegium Pharmaceutical Inc be the next market leaderMarket Movers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Collegium Pharmaceutical, Inc. (COLL) gains momentum on Jornay PM, Truist highlights robust pain portfolio - MSN
Dow Update: Will Collegium Pharmaceutical Inc benefit from green energy policiesTrade Volume Report & Smart Money Movement Alerts - baoquankhu1.vn
(COLL) Volatility Zones as Tactical Triggers - Stock Traders Daily
Pharma News: Can Collegium Pharmaceutical Inc benefit from deglobalizationQuarterly Market Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Finanzdaten der Collegium Pharmaceutical Inc-Aktie (COLL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.75%
1.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):